Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Power estimation for non-standardized multisite studies.
Incorporating Alcohol Pharmacotherapies Into Medical Practice
Effects of delayed-release dimethyl fumarate on MRI measures in the Phase 3 DEFINE study.
NICE recommends new treatment option for multiple sclerosis (Dimethyl fumarate)
Pervasive Axonal Transport Deficits in Multiple Sclerosis Models.
Serum 25-hydroxyvitamin D levels and risk of multiple sclerosis.
Daclizumab HYP versus Interferon Beta-1a in Relapsing Multiple Sclerosis.
Teva Pharmaceutical Industries Limited's CEO Discusses Q1 2012 Results - Earnings Call Transcript
Vitamin D receptor-retinoid X receptor heterodimer signaling regulates oligodendrocyte progenitor cell differentiation.
Extension CombiRx data show no benefit of combined MS drugs
Autoimmune Hepatitis-like reaction developing in a patient treated with Interferon beta 1a.
A Pilot Trial of Interferon beta-1a in Alzheimer's Disease
Less Frequent and Less Severe Flu-Like Syndrome in Interferon Beta-1a Treated Multiple Sclerosis Patients with at Least One Allele Bearing the G>C Polymorphism at Position -174 of the IL-6 Promoter Gene.
Long-term use of glatiramer acetate by 11 pregnant women with multiple sclerosis: a retrospective, multicentre case series.
A benefit-risk analysis of natalizumab in the treatment of patients with multiple sclerosis when considering the risk of progressive multifocal leukoencephalopathy.
Benign multiple sclerosis: a distinct clinical entity with therapeutic implications.
Focal vibration in neurorehabilitation.
Treatment of multiple sclerosis with the pregnancy hormone estriol.
Association of Immunotherapies With Outcomes in Relapsing-Remitting Multiple Sclerosis.
Immune competence after alemtuzumab treatment of multiple sclerosis.
New analysis shows Novartis drug Gilenya® significantly reduced rate of brain volume loss across three large Phase III studies
Alemtuzumab long-term immunologic effect: Treg suppressor function increases up to 24 months.
Severe liver dysfunction possibly caused by the combination of interferon beta-1b therapy and melilot (sweet clover) supplement.
MRI criteria for the diagnosis of multiple sclerosis: MAGNIMS consensus guidelines.
Keystone Symposium: Multiple Sclerosis

Pages